---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-069674"
form_type: "8-K"
ticker: "RLAY"
cik: "0001812364"
company_name: "Relay Therapeutics, Inc."
filed_at: "2024-06-06T23:59:59+00:00"
generated_at: "2026-06-01T05:59:05.797020+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Relay Therapeutics announces Pfizer collaboration and three new pipeline programs

## Summary
- Clinical collaboration with Pfizer to evaluate RLY-2608 + atirmociclib + fulvestrant in PI3Kα-mutated HR+/HER2- metastatic breast cancer; initiation planned by end of 2024.
- New pre-clinical programs: vascular malformations, Fabry disease non-inhibitory chaperone, and NRAS-selective inhibitor, targeting over 200,000 U.S. patients.
- RLY-2608 clinical development in vascular malformations expected Q1 2025; Fabry disease chaperone and NRAS inhibitor to enter clinic in H2 2025.
- Cash runway guidance unchanged; $750 million expected to fund operations into second half of 2026.

## SEC filing metadata
- accession: 0000950170-24-069674
- form_type: 8-K
- ticker: RLAY
- cik: 0001812364
- company_name: Relay Therapeutics, Inc.
- filed_at: 2024-06-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1812364/000095017024069674/0000950170-24-069674-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1812364/000095017024069674/rlay-20240605.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-069674
- JSON: https://secwatch.observer/filing/0000950170-24-069674.json
- Plain text: https://secwatch.observer/filing/0000950170-24-069674.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.